Login to Your Account

Reg A Revival

Creating an IPO Alternative for Small Biotechs

By Trista Morrison

Monday, November 21, 2011

Of the four Congressional bills aimed at providing small companies with new fundraising options, H.R. 1070 – which would allow private firms to raise up to $50 million publicly and trade their shares without the expense of becoming a reporting company – is likely to have the most immediate impact on biotech.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription